Introduction {#Sec1}
============

Neurological complications are well recognised in influenza infection, with different strains demonstrating varying degrees of neurovirulence \[[@CR17], [@CR34]\]. The "Spanish Flu" pandemic of 1918--1930, estimated to have infected 500 million people and claimed 40 million lives, caused major central nervous system morbidity \[[@CR34]\]. More recently, the epidemic influenza A (H3N2) strain was associated with a surge in cases of encephalitis/encephalopathy in Japan \[[@CR18], [@CR28], [@CR46]\], Europe \[[@CR40]\] and America \[[@CR25]\]. The spectrum of neurological conditions arising from neurovirulent strains of influenza includes seizures \[[@CR4], [@CR25], [@CR40]\], acute necrotising encephalopathy (ANE) \[[@CR30], [@CR40], [@CR42], [@CR44]\], Reye's syndrome \[[@CR3]\], transverse myelitis \[[@CR21]\], acute disseminated encephalomyelitis \[[@CR21]\], Guillain--Barre syndrome \[[@CR9], [@CR21]\], mutism \[[@CR29]\] and movement disorders \[[@CR37]\].

The pandemic influenza A 2009 H1N1 virus spread worldwide claiming over 18,400 lives \[[@CR35]\] with a notable predominance of disease burden and mortality in children \[[@CR13], [@CR32], [@CR38]\]. In England, the paediatric mortality was estimated at six per million (70 cases) from an observational population-based study \[[@CR38]\]. Thus far, neurological complications have been reported in 26 paediatric cases from three case series from America \[[@CR2], [@CR7], [@CR8]\] and in 38 additional cases worldwide \[[@CR1], [@CR5], [@CR11], [@CR14], [@CR16], [@CR22]--[@CR24], [@CR26], [@CR31]--[@CR33], [@CR36], [@CR39], [@CR41], [@CR43], [@CR45]\]. Table [1](#Tab1){ref-type="table"} details the neurological presentation and outcome of these paediatric cases. In this paper, we report the neurological manifestations and outcomes of children who presented to a single UK institution with the 2009 H1N1 virus infection and review their neurological complications in conjunction with the previously reported cases from this epidemic worldwide. Table 1Comparison of the neurological presentation, investigations and outcome of children reported in the literature with 2009 H1N1 virus-associated neurological complicationsAgeSexCo-morbidityNeurological presentationCNS neuroimaging^a^EEGHospital stayCSF^b^Outcome^c^Acevedo et al. \[[@CR1]\]13MNoneMutism, sleep and hypersexual behaviourNormalNormal10NormalLevel 1Baltagi et al. \[[@CR2]\]10MNoneEncephalopathyNormalDiffuse slowing5NormalLevel 14MNoneEncephalopathyNormalDiffuse slowing--NormalLevel 12FNoneSeizures, encephalopathy, movement disorderInitial: normal; repeat: increase volume loss and subtle signal changeDiffuse slowing60NormalLevel 33FNoneEncephalopathyANEDiffuse slowing19NormalLevel 3 (at 5 months level 2Choi et al. \[[@CR5]\]17MNoneSeizureNormalNon-specific--15 WBCLevel 2 (AED)Ekstrand et al. \[[@CR7]\] (individual patient, details not available)0.3--14.58 M 10 F8 Medical12 Patients had seizuresOut of 7 imaged, 2 had mutifocal sub-cortical white matter attenuation in T2 sequence8 Abnormal EEG results out of 11 screenedMedian length 2 days (0.5--30 days)All evaluated patients normal (10)11 Level 16 neurological (1 epilepsy, 3 febrile seizures, 1 muscle disease and 3 delay in development)7 had status epilepticusOne had multifocal T2 signal changes in both cortical and sub-cortical white mattersDiffuse slowing, spike and wave discharges, burst suppression pattern4 patients level 2/3 (2 patients improved after 6 months)9 had encephalopathy2 patients level 2 (AED) 1 patient- level 43 had headache5 had focal neurological signs6 had aphasiaEvans et al. \[[@CR8]\]17MNoneEncephalopathyNormalNormal4NormalLevel 110MNoneSeizures, encephalopathySingle punctuate calcification in left frontal cortexSlowing without epileptogenic focus7NormalLevel 2 (AED)7MFebrile seizuresSeizuresNormalParietal slowing without epileptogenic focus3NormalLevel 2 (AED)11MAsthmaEncephalopathyNormalPosterior slowing without epileptiform activity4NormalLevel 1German-Diaz et al. \[[@CR11]\]13MNoneEncephalopathy with delirium and aggressionCT scan normalConsistent with encephalopathy10NormalLevel 1Haktanir et al.\[[@CR14]\]3FNoneSeizure and encephalopathyBilateral thalamic and perirolandic hyperintensities----Normal--Iwata et al. \[[@CR16]\]14MPrevious encephalitisDysarthria, dysphagia, mild ptosis and encephalopathyTransient high intensity signal in splenium and white matter--9NormalLevel 1Lister et al.\[[@CR22]\]10MNoneSeizure and encephalopathy----6----Lyon et al.\[[@CR23]\]12FNoneEncephalopathyANE--3--Level 4Mariotti et al. \[[@CR24]\]2FNoneEncephalopathyANESlow background--NormalLevel 2Martin et al.\[[@CR26]\]7FNoneEncephalopathyANE--3--Level 4O'Leary et al. \[[@CR31]\]0.8MNoneComplex febrile seizuresNormal CTNormal4--Level 1O'Riordan et al.\[[@CR32]\]------10/17 had neurological impairment----------Ormitti et al.\[[@CR33]\]3FNoneSeizure, encephalopathyANE----6 WBCLevel 3Rellosa et al. \[[@CR36]\]5MNoneEncephalopathyCT on day 2 normal MRI on day 8, sub-cortical white matter T2 hyperintensities, consistent with ADEMComplex partial status epilepticus2732 WBC Elevated proteinLevel 22MNoneSeizuresCT normal, MRI none initially, follow-up MRI at 2 months normalBilateral frontal spike wave5NormalLevel 2 (AED) 2 months9MNoneLethargy progressing to mutism and unresponsivenessCT: normal, MRI: bilateral increased signal and heterogeneity of basal ganglia, thalamus and spleniumDiffuse background slowing with intermittent rhythmic delta waves612 WBC, elevated proteinLevel 1Sanchez-Torrent et al. \[[@CR39]\]0.3MNoneSeizures, sleepiness, hypotoniaNormal CTDiffuse slowing1030 WBC 1,160 RBCLevel 1Tan et al.\[[@CR41]\]16FNoneSeizureNormal------Level 116FFebrile seizuresSeizureBrain atrophyNormal----Level 115MNoneSeizure--------Level 1Webster et al.\[[@CR43]\] Mar 105FNoneEncephalopathy, focal status epilepticus and left hemiplegiaHigh signal of the right parieto-occipital cortexRight posterior spike and wave activity7--Level 15MNoneAscending paralysis, leading to quadriplegia and comaHigh signal in the medulla and cervical cord, right frontal and left posterior periventricular white matter--14--Level 2Yildizdas et al. \[[@CR45]\]6FNoneEncephalopathy----5Raised WBCLevel 16MNoneSeizure and encephalopathyDiffuse cortical and perirolandic T2 hyperintensitySharp waves on right temporal occipital regions19NormalLevel 10.8FNoneSeizure and encephalopathyCT Diffuse oedemaSpikes, slow waves in mid and posterior regions of L hemisphere11--Level 13MNoneSeizure and encephalopathyNormalNormal8--Level 14FChronic renal failureSeizure and encephalopathyANE--2--Level 43MWest syndromeSeizure and encephalopathy--Severe irregular rhythm5NormalLevel 1^d^6FCerebral Palsy, epilepsySeizure and encephalopathy--Normal6--Level 1^d^7FCerebral Palsy, epilepsySeizure and encephalopathy--Seizure activity noted9NormalLevel 1^d^Outcome level 1, normal; level 2, mild sequelae; level 3, severe sequelae requiring help for personal daily activities; level 4, death*AED* anti-epileptic drugs, *ANE* acute necrotising encephalopathy, *ADEM* acute disseminated encephalomyelitis, *M* male, *F* female^a^MRI unless otherwise stated^b^Only abnormal parameter denoted (WCC cells/μL; RBC cells/μL; protein in g/dL; glucose in mmol/L)^c^Outcome at discharge unless otherwise stated^d^Back to pre-morbid state, data not available

Methods {#Sec2}
=======

Patient selection and case definitions {#Sec3}
--------------------------------------

The Evelina Children's Hospital (ECH) admits children under the age of 16 years from the local population and is the regional referral centre for paediatric intensive care, neurology and infectious disease for South East London. ECH has 140 paediatric beds, admits 20,000 children annually and serves a population of seven million (1.5 million children). Hospital data (case notes) of all children hospitalised with the 2009 H1N1 virus infection identified from microbiological records between 1 April 2009 to 31 March 2010 were reviewed. A child with acute neurological complications associated with the 2009 H1N1 virus infection was defined as having laboratory-confirmed infection with seizures, encephalopathy, encephalitis or any focal neurological syndrome (e.g. ataxia) within 1 week of an influenza-like symptom. Children with pre-existing epilepsy who presented with seizures were excluded. Encephalopathy was defined as altered level of consciousness for more than 24 h, including lethargy, irritability or change in personality and behaviour \[[@CR12]\]. Encephalitis was diagnosed when encephalopathy was present with two or more of: fever or history of fever (≥38°C), seizures and/or focal neurological findings (with evidence of brain parenchyma involvement), cerebrospinal fluid (CSF) pleocytosis (\>4 white blood cells/μl), electroencephalogram (EEG) findings in keeping with encephalitis and neuroimaging in keeping with encephalitis \[[@CR12]\].

2009 H1N1 virus infection was confirmed by detection of influenza viral ribonucleic acid (RNA) in upper respiratory tract (throat/nasal swabs) or lower respiratory tract (bronchoalveolar lavage fluid) specimens. Reverse transcriptase polymerase chain reaction was performed using primers and probes specific for the haemagglutinin gene of the 2009 H1N1 virus according to a method standardised by the Health Protection Agency of the United Kingdom \[[@CR15]\]. Respiratory samples were also processed to detect concurrent infection with seasonal influenza A and B viruses, respiratory syncytial viruses A and B, parainfluenza viruses 1--4, adenovirus, human metapneumovirus, entero/rhinoviruses, human coronaviruses and bocavirus using a multiplex PCR method. Serological tests were performed to exclude recent infection with cytomegalovirus, Epstein-Barr virus, *Mycoplasma pneumoniae* and *Toxoplasma gondii*. CSF samples were investigated for herpes simplex virus (HSV) deoxyribonucleic acid (DNA), varicella--zoster virus DNA, enterovirus RNA and 2009 H1N1 virus RNA.

Outcomes were defined as previously described: level 1, normal; level 2, mild sequelae; level 3, severe sequelae requiring help with personal daily activities and level 4, death \[[@CR28]\]. All patients have up to a minimum of 9 months follow-up period. This study was conducted as a retrospective note review. Consent was obtained from the five patients for the reporting of the case history.

Results {#Sec4}
=======

Eighty-three children were admitted with 2009 H1N1 virus infection, of which five had neurologic symptoms. Table [2](#Tab2){ref-type="table"} summarises the clinical characteristics, treatment and outcome, and Table [3](#Tab3){ref-type="table"} illustrates the investigation of the five patients. Table 2Clinical presentation, treatment and outcome of the children with neurological complications of 2009 H1N1 virus infection at Evelina Children's HospitalCase 1Case 2Case 3Case 4Case 5Age at presentation2 years 10 months4 years 6 months10 years 5 months5 years 5 months10 monthsSexMaleFemaleMaleFemaleMaleRaceAfrican CarribeanCaucasianAsianCaucasianCaucasianPast medical historyFebrile convulsions mild speech delayNoneNoneAsthmaDown's syndromeDuration to neurological symptoms3 days2 days7 days2 days7 daysSeizures++++−Encephalopathy−++++Encephalitis−++−−Fever, °C3838.9394040Antiviral therapyOseltamivirOseltamivir, changed to zanamavirOseltamivirOseltamivirOseltamivirIVIG 1 course = 1 g/kg/day for 2 daysNone1 course3 courses, 1 month apart1 courseNoneOutcomeLevel 2Level 1Level 3Level 3Level 1*IVIG* intravenous immunoglobulin, *+* present, − absent, *outcome level 1* normal resolution, *level 2* mild sequelae, *level 3* severe sequelae requiring personal help for daily activities, *level 4* death Table 3Laboratory investigations, neuroimaging and EEG findings of the children with neurological complications of H1N1 virus infection at Evelina Children's HospitalCase 1Case 2Case 3Case 4Case 5C reactive protein (mg/L)1125101646Blood cultureNo growthNo growthNo growthNo growthNo growthUrine cultureNo growthNo growthNo growthNo growthNo growthCPK (IU/l)200Not done69192932AST (IU/l)2223256516MRI brainNon-specific parietal--occipital white matter changes with minimal acute inflammationHigh signal involving the dentate nuclei, pons, midbrain and thalamiInitial: normal; at 2 months: subtle and vague increased signal in a periventricular distribution bilaterallyInitial: normal; at 3 weeks: significant loss of cerebral volumeCT brain normalEEGBackground 1--2 Hz slow wave activityGeneralised high-amplitude 1--2-Hz delta activityHigh-amplitude generalised slow waves with no epileptiform discharges1--2.5 Hz slow background activity with no epileptiform activityNot doneCSFWhite cell\<1\<116^a^\<11Red cell\<1\<11510Protein (g/l)0.290.530.20.070.12Glucose (mmol/l)3.63.63.843.3CultureNo growthNo growthNo growthNo growthNo growthH1N1 PCRNegativeNegativeNegativeNegativeNegativeOligoclonal bandsNot doneNegativeNot doneNegativeNot done*CK* creatine phosphokinase, *AST* aspartate aminotransferase, *CSF* cerebrospinal fluid^a^Repeat CSF was normal (4, white cell; 65, red cell)

Patient reports {#Sec5}
---------------

### Case 1 {#Sec6}

A 3-year-old Afro-Caribbean boy presented with three self-limiting febrile seizures following 3 days of fever and coryza. He developed generalised afebrile seizures and truncal ataxia on day 2. Brain magnetic resonance imaging (MRI) on that day showed parietal--occipital white matter changes. EEG showed 1--2 Hz slow wave activity with no epileptic discharges, and CSF analysis was normal. He was treated with intravenous (IV) acyclovir, IV cefotaxime and oral clarithromycin. Respiratory secretions tested positive for 2009 H1N1 virus RNA; he was commenced on oral oseltamivir. His ataxia improved, and at discharge (day 4), he was seizure-free. He was readmitted 8 days later having more seizures but remained neurologically normal. Repeat CSF analysis and brain MRI were unchanged. Seizure control was achieved by sodium valproate and phenytoin. One year later, he is seizure-free and off anticonvulsants but had significant delay in personal and social skills (outcome 2).

### Case 2 {#Sec7}

A 4-year-old Caucasian girl presented with a 20-min generalised, tonic--clonic seizure following 2 days of fever and coryza. She was pyrexial (38.9°C) and had a herpetic lesion (HSV type 1 DNA-positive) on her upper lip. Seizures continued warranting sedation and ventilation. She was commenced on IV ceftriaxone, IV acyclovir and oral oseltamivir. 2009 H1N1 virus RNA was detected in upper and lower respiratory samples. CSF analyses were negative for H1N1 and HSV PCR. EEG on day 2 showed continuous generalised slow wave activity with no epileptiform discharges. She remained encephalopathic and developed upper motor neuron signs. Brain MRI on day 2 was suggestive of ANE. Due to the clinical and neuroimaging severity, she was given intravenous immunoglobulin (IVIG), and oral oseltamivir therapy was empirically converted to IV zanamivir. Her clinical recovery was excellent with neurological normalisation over 7 days. At 3 and 9 months, she remained neurologically normal and had fully integrated back in school (outcome 1).

### Case 3 {#Sec8}

A 10-year-old Asian boy was admitted following a 10-min generalised seizure. He had a flu-like illness a week prior but had not been prescribed oseltamivir. He was drowsy but had no focal neurological signs. Brain computed tomography (CT) was normal, and CSF showed mild pleocytosis. He was treated with IV acyclovir, IV ceftriaxone, oral clarithromycin and oral oseltamivir. Upper respiratory tract sampling was positive for the 2009 H1N1 virus. Frequent seizures persisted, and EEG on day 5 showed high-amplitude generalised slow waves but no epileptiform discharges. Deterioration in seizure control necessitated sedation and ventilatory support. Brain MRI and repeat CSF analysis were normal. He received IVIG as an immune-mediated encephalopathy was suspected. Quadruple anticonvulsant therapy achieved sufficient seizure control to allow extubation after 10 days. Drowsiness, marked choreoathetoid movements, aphasia and motor weakness gradually improved, although seizure control was not sustained. Episodes of acute confusional state and aggression responded to risperidone therapy. He was discharged after 6 weeks, still having frequent focal and generalised seizures. He had two further courses of IVIG at monthly intervals. Repeat brain MRI at 3 months showed subtle increased signal in a periventricular distribution bilaterally. Neuro-metabolic investigations showed no evidence of an aminoacidaemia, organicacideamia, urea cycle or fatty oxidation defect. There was no identifiable evidence of an autoantibody-mediated encephalopathy. One year after the acute illness, his seizures remain refractory to treatment, necessitating admission to a specialised inpatient hospital educational setting. Personal care and learning are affected by significant neuropsychometric deficits in memory and executive functioning (outcome 3).

### Case 4 {#Sec9}

A 5-year-old Caucasian girl presented with unabating seizures preceded by 2 days of cough, coryza and fever. Seizures were refractory to initial therapies and were ultimately terminated by thiopentone and midazolam infusion. She required ventilatory support, significant fluid resuscitation (50 ml/kg) for hypotensive shock as well as inotropic support for 48 h. She was commenced on IV ceftriaxone, IV acyclovir and oral oseltamivir. Her throat/nasal swab was positive for the 2009 H1N1 virus. Brain MRI scan on day 2 and CSF analysis on day 3 were normal. EEG on day 3 showed generalised 1--4 Hz slow waves with no epileptiform activity. Sustained seizure control was achieved after 4 days. She developed dyskinetic movements and dystonic posturing. There was little improvement following IVIG on day 6. EEG on day 12 was unchanged with no epileptiform activity corresponding with dyskinetic movements. Repeat MRI brain after 3 weeks showed significant cerebral volume loss and non-specific white matter changes in the right posterior parietal region. Neuro-metabolic investigations (as detailed for case 3) and autoantibody-mediated encephalopathy were negative. When reviewed at 4 months, seizures were well controlled, with resolution of her movement disorder, but at 11 months review, she exhibited significant cognitive impairment and social communication difficulties, requiring education in a special school (outcome 3).

### Case 5 {#Sec10}

An 8-month-old Caucasian boy with Down's syndrome had 7 days of cough and temperature prior to presenting with an unresponsiveness episode lasting for 10 min. He was encephalopathic and had mild respiratory distress requiring oxygen. Chest X-ray revealed bilateral peri-hilar consolidation. He was treated with IV ceftriaxone, IV acyclovir and oral clarithromycin for presumed meningo-encephalitis with pneumonia. After initial improvement in alertness, his level of consciousness reduced on day 3 associated with poor respiratory effort, necessitating ventilatory support. Respiratory secretions were positive for 2009 H1N1 virus, and oseltamivir was started. The remainder of the septic screen including CSF was negative. CT brain was normal. Following extubation, his neurological function was normal. He was discharged by day 8 and had fully recovered at 6 weeks, remaining neurologically well at 1 year review (outcome 1).

Discussion {#Sec11}
==========

The Evelina Children's Hospital in London managed a large number of hospitalised H1N1 cases, including six of England's 51 H1N1-associated in-hospital paediatric deaths \[[@CR38]\]. Thirty percent (22/70) of the paediatric deaths in England presented with encephalopathy or seizures \[[@CR38]\]. After death, neurological sequelae are amongst the most severe consequences of pandemic influenza A H1N1 infection in children \[[@CR38]\]. Compared with children presenting with seasonal influenza, patients with 2009 H1N1 infections had more severe neurological complications (encephalopathy and focal neurology), whilst the incidence of seizures and status epilepticus were similar across both groups \[[@CR7]\].

Neurological presentation and CSF investigation {#Sec12}
-----------------------------------------------

The rate of neurological complications in children with 2009 H1N1 virus infection hospitalised to our institute was 6% (5/83) compared with 2% in the Pittsburg series \[[@CR2]\], 7% in Utah \[[@CR7]\], 10% in Turkey \[[@CR45]\] and 15% in Texas \[[@CR8]\]. Demographic data available for our cohort indicated that only one patient with neurological complication was from our local population (2%; 1/53) compared with the four patients referred from the region either via the intensive care unit or paediatric neurology service (13%, 4/30), highlighting the referral bias with referred patient tending to be more severely affected and having more neurological complications. Thus, the variation of incidence ranging from 2% to 15% from various studies is likely to reflect either the referral bias of the reporting institution or the inclusion of patients with underlying seizure disorder or neurological conditions.

Seizures and altered sensorium were the most common neurological symptoms, occurring in four of five patients in our series. Four of the five patients presented with encephalopathy, of which two met the criteria for encephalitis. Three of our patients required intensive care support for control of seizures and one for encephalopathy. Such severity of neurological complications associated with 2009 H1N1 influenza virus accords with that reported in the largest American series where ten out of 18 patients required intensive care admission \[[@CR7]\]. Two of our patients developed both seizures and movement disorders; one developed neuropsychiatric manifestation during the disease evolution and is only the second reported case of this complication associated with the 2009 H1N1 pandemic strain \[[@CR11]\]. Movement disorders following viral encephalitis have generally been associated with basal ganglia involvement \[[@CR20], [@CR21], [@CR37]\]. Interestingly, while two of the cases reported here developed a movement disorder in the convalescent phase, neither had evidence of basal ganglia involvement on neuroimaging. The abnormal movements improved in both cases at follow-up.

Inclusive of our five cases, 62% (37/59; data not available in ten) of all reported cases of 2009 H1N1 with related neurological complications had seizures at presentation while 69% (41/59) had features of encephalopathy (Table [1](#Tab1){ref-type="table"}). Thirteen percent (8/59) of patients had focal neurological signs at presentation. The novel H1N1 strain has been detected in CSF in only one case to date, although that result was possibly attributable to traumatic lumbar puncture \[[@CR39]\], a finding similar to influenza associated encephalopathy (IAE) induced by other strains of influenza where CSF viral isolation has been a rarity \[[@CR10], [@CR46]\]. In our series, CSF pleocytosis was only seen in one case (case 3), comparable to the 18% (7/38) reported in the literature.

Neuroimaging {#Sec13}
------------

Of the 69 reported cases, brain neuroimaging data was available in 42. Neuroimaging was normal in 42% (18/42) of patients. Cortical and sub-cortical white matter signal changes (16%; 7/42) and neuroimaging features of ANE (17%; 7/42) are the commonest neuroimaging changes described. The importance of acute and follow-up neuroimaging is underlined by our series. Acutely, only two of our five cases had abnormal neuroimaging: one showed evidence of ANE and another showed non-specific white matter changes. Although initial neuroimaging was normal for the other three patients, the interval MRI was abnormal in two. One showed increased signal in periventricular distribution bilaterally, the other revealed significant loss of cerebral volume. Normal acute imaging followed by brain atrophy is well described with IAE, most patients being left with marked neurological sequelae \[[@CR2], [@CR46]\], as in our patient. Patients infected with the 2009 H1N1 strain with ANE, basal ganglia involvement and volume loss on neuroimaging had poorer outcome (Table [1](#Tab1){ref-type="table"}).

Treatment {#Sec14}
---------

All five cases in this series were treated with oseltamivir (Roche, Welwyn Garden City, England). Case 2 was empirically changed to IV zanamivir due to the severity of this child's clinical condition and the potential severity of outcome associated with ANE and because of the potential of oseltamivir resistant virus. IV zanamivir was supplied on a compassionate basis by Glaxo-Smith-Kline (Brentford, England) and is thought to carry the same efficacy as oseltamivir \[[@CR19]\]. Although the use of antiviral medications can decrease the risk of complications from influenza \[[@CR6], [@CR27]\], specific neuro-therapeutic effect is uncertain \[[@CR25]\]. In line with previous reports, it was not possible to determine whether antiviral treatment decreased the severity or improved neurological outcome in this series or in the other reported cases.

IVIG was given in three patients for potentially immunomodulatory effects, indicated by the severity of presentation. While the timing of IVIG administration may influence its likelihood of conferring benefit, this series is too small to allow any inference to be drawn. There was little evidence of benefit in two patients. The third patient, with ANE, made complete recovery (case 2). This clinical outcome is unusual when compared with reported cases \[[@CR2], [@CR23], [@CR24], [@CR26], [@CR33], [@CR45]\] but cannot be attributed to any individual therapeutic intervention given the complex multi-therapeutic interventions the child received concurrently.

Outcome {#Sec15}
-------

In the Japanese study involving influenza A and B strains, elevated serum aspartate aminotransferase and creatine phosphokinase (CPK), and thrombocytopenia (\<50,000 platelets/μl) appeared to correlate with unfavourable outcome in influenza-associated encephalopathy \[[@CR28]\]. None of our cases had liver function abnormalities or thrombocytopenia; two had elevated CPK of more than 600 IU/L, both of which had poorer outcome. The cases presented in this series had varied outcomes. Two children (cases 2 and 5) recovered fully. Three patients developed seizure disorders; at 1 year, two have ongoing seizures (cases 3 and 4), one of which remains intractable to treatment. Three patients were left with mild (case 1) to severe (cases 3 and 4) cognitive impairment.

Out of the four deaths with neurological complications thus far reported, three were due to ANE \[[@CR23], [@CR26], [@CR45]\] and one was due to associated respiratory failure \[[@CR7]\]. Twelve of the 57 cases (18%; data not available in 12) required treatment with anti-epileptic medication and 12% (7/57) had significant neurological sequelae (Table [1](#Tab1){ref-type="table"}). Although 65% (34/52) of patients were reported to have full recovery at discharge, longer-term follow-up of cases may indeed reveal additional cognitive impairment. Conversely, neurologically abnormal patients at discharge may indeed improve over time \[[@CR2], [@CR7]\]. Only longer-term follow-up will precisely determine the neurological burden of 2009 H1N1 influenza virus.

Conclusion {#Sec16}
==========

Seizures and encephalopathy are the common neurological phenotype associated with pandemic 2009 H1N1 influenza virus infection in children. While we await the emerging epidemiology of H1N1 and other strains of influenza in coming seasons, early consideration of influenza strains as a cause when children present with neurologic symptoms is advocated, given the potential for significant long-term sequelae especially in previously healthy children (57% of reported cases; 34/59). Normal neuroimaging at presentation should not be over-interpreted; interval imaging is advocated if recovery is not swift. Neuroimaging suggestive of ANE, basal ganglia involvement and volume loss appears to be associated with worse neurological outcome. Whether early treatment with antiviral drugs improves neurological outcome is unknown, but until there is evidence to guide management, early antiviral therapy is advocated. The role of immunomodulatory adjuvant therapy, however, remains speculative and likely should be reserved for the most severe cases.
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